Equities research analysts at Chardan Capital assumed coverage on shares of Vicore Pharma (NASDAQ:VCRE – Get Free Report) in a report issued on Wednesday, Benzinga reports. The firm set a “buy” rating and a $15.00 price target on the stock. Chardan Capital‘s target price suggests a potential upside of 58.90% from the stock’s previous close.
A number of other brokerages have also weighed in on VCRE. Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a report on Friday, October 9th. They issued a “buy” rating and a $25.00 price objective for the company. Wall Street Zen upgraded shares of Vicore Pharma to a “hold” rating in a research report on Saturday, October 24th. Finally, Weiss Ratings initiated coverage on shares of Vicore Pharma in a research note on Thursday, October 8th. They issued a “sell (e-)” rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vicore Pharma presently has a consensus rating of “Hold” and a consensus target price of $20.00.
Get Our Latest Stock Analysis on VCRE
Vicore Pharma Trading Up 3.1%
VCRE traded up $0.28 during midday trading on Wednesday, reaching $9.44. The company had a trading volume of 25,161 shares, compared to its average volume of 26,943. Vicore Pharma has a 12-month low of $7.88 and a 12-month high of $17.80.
Vicore Pharma (NASDAQ:VCRE – Get Free Report) last posted its quarterly earnings results on Friday, August 21st. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter.
Vicore Pharma Company Profile
Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.
Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.
See Also
- Five stocks we like better than Vicore Pharma
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
